DEVA COVID19
Alternative Names: DEVA-COVID19; ONCoat™ Synthetic Vector Vaccine - DevaCell; SARS-CoV19 infectious disease vaccine - DevaCellLatest Information Update: 29 Apr 2021
At a glance
- Originator DevaCell
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 06 Jan 2021 Preclinical trials in COVID-2019 infections in USA (Parenteral), prior to January 2021 (DevaCell pipeline, March 2021)
- 06 Jan 2021 DevaCell plans an IND-enabling study for COVID-2019 infections (DevaCell pipeline, March 2021)